Cetuximab in mucinous peritoneal carcinomatosis: Assessment by serial CA19.9 and CEA measurements

Eleni Andreopoulou(Cornell University), Franco M. Muggia(NYU Langone Health), David Mauro(Merck & Co., Inc., Rahway, NJ, USA (United States)), Howard S. Höchster(Rutgers, The State University of New Jersey), Elliot Newman(Bristol-Myers Squibb (United States)), Malek M. Safa(Bristol-Myers Squibb (United States)), Andrew M. Lowy(UC San Diego Health System), Theresa Ryan(Bristol-Myers Squibb (United States)), Juliet Escalon(Bristol-Myers Squibb (United States)), Andrea Downey(University of New Mexico)
Unknown
May 1, 2007
Cited by 0

Related Papers

Cetuximab-Induced Anaphylaxis and IgE Specific for Galactose-α-1,3-Galactose
|New England Journal of Medicine|2008|1.5k
Rectal Cancer, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2018|998
Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With <i>KRAS</i> Wild-Type Advanced or Metastatic Colorectal Cancer
|JAMA|2017|891
Safety and Efficacy of Oxaliplatin and Fluoropyrimidine Regimens With or Without Bevacizumab As First-Line Treatment of Metastatic Colorectal Cancer: Results of the TREE Study
|Journal of Clinical Oncology|2008|623
Randomized Trial of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF-Mutant Metastatic Colorectal Cancer (SWOG S1406)
|Journal of Clinical Oncology|2020|391